IGC Pharma (IGC) Stock Price
IGC Pharma Price
Revenue at IGC Pharma has contracted by 3.3% per year over the past 18 years to 1.19 M USD. For IGC Pharma, the net margin of -552.1% is up versus -3,782.4% a few years ago.
IGC Pharma stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
IGC Pharma business model & stock analysis
Frequently asked questions about IGC Pharma
The business model of India Globalization Capital Inc (IGC) revolves around various sectors, including infrastructure, technologies, and pharmaceuticals. IGC primarily focuses on the development and commercialization of cannabis-based therapies to address various medical conditions. By leveraging their in-house research and expertise, IGC aims to create innovative cannabis formulations that can potentially improve patient outcomes and quality of life. Additionally, the company also engages in the leasing of heavy equipment, mining exploration, and reclamation of high-grade iron ore to generate sustainable revenue. Through their diversified business segments, IGC strives to deliver value to its shareholders and contribute to the evolving medical and infrastructure sectors.
India Globalization Capital Inc is primarily active in the industries of infrastructure, real estate, and pharmaceuticals.
The main competitors of India Globalization Capital Inc in the market include companies such as Canopy Growth Corporation, Aurora Cannabis Inc, and Tilray Inc. These companies operate in the same industry and compete with India Globalization Capital Inc in areas such as cannabis-based pharmaceuticals, and alternative therapies and treatment solutions. India Globalization Capital Inc aims to differentiate itself through its proprietary intellectual property and innovative approaches in the market. However, it faces strong competition from these established players who also have a significant market presence and drive advancements in the industry.
India Globalization Capital Inc. (IGC) is a prominent company founded in 2005. The company primarily operates in various sectors like infrastructure, plant extraction, and traditional Chinese medicine. With a vision to become a global leader, IGC focuses on informational technology-related products and services to fulfill evolving market needs. Throughout its history, IGC has successfully developed and commercialized a range of patented therapies, enhancing consumer healthcare experiences and quality of life. The company's commitment to innovation and diversified business portfolio have contributed to its substantial growth and recognition within the industry. IGC continues to strive towards providing cutting-edge solutions and driving positive advancements in various fields of operation.
India Globalization Capital Inc (IGC) has achieved several significant milestones over the years. One of the notable achievements is the company's entry into the medical cannabis market. By leveraging its expertise in plant-based therapies and advanced pharmaceutical technologies, IGC has developed a portfolio of cannabinoid-based combination therapies. This pioneering move has positioned the company uniquely in the industry, creating opportunities for substantial growth and market penetration. Moreover, IGC has successfully obtained multiple patents and intellectual property rights, solidifying its position as a leading player in the medical cannabis space. The company's dedication to innovation and strategic partnerships has enabled it to pave the way for novel treatments and carve a niche for itself in the market.
India Globalization Capital Inc (IGC) is primarily present in India and the United States. With its headquarters in Bethesda, Maryland, USA, IGC operates in various states across India and has a significant presence in its home country. The company focuses on developing and commercializing cannabis-based pharmaceutical and natural wellness products, as well as providing services to the telecommunications and infrastructure sectors. As a global player, IGC aims to leverage its expertise and strategic partnerships to expand its presence in other regions and countries, capitalizing on emerging market opportunities worldwide.
India Globalization Capital Inc (IGC) represents a strong commitment to innovation, growth, and value creation. With a focus on rapidly expanding markets, IGC leverages its expertise in developing and commercializing transformative products and solutions. The company's corporate philosophy centers around delivering exceptional shareholder value, fostering long-term partnerships, and adhering to the highest standards of corporate governance and ethics. By staying attuned to market trends and continuously enhancing its offerings, IGC stands as a leading player in sectors like cannabis-based therapies, specialty pharmaceuticals, and infrastructure. IGC's dedication to excellence and strategic approach underscores its mission to enhance the lives of millions through pioneering technologies and forward-thinking strategies.
5 analysts currently rate the IGC Pharma stock: 4 recommend buying, 1 holding and 0 selling.
Converted at the current exchange rate, the IGC Pharma share trades at 0.18 EUR (0.20 USD).
The IGC Pharma share (IGC) is listed on 3 stock exchanges, including: Frankfurt (IGS1.F), München (IGS1.MU).
India Globalization Capital Inc. is a diversified company that operates in various industries including construction and infrastructure, heavy industry, agricultural and food production, as well as dietary supplements.
The revenue of IGC Pharma is 1.19 M USD. This figure is based on current financial data and reflects the company's business performance.
The profit of IGC Pharma is -6.55 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of IGC Pharma is currently -3.13. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the IGC Pharma stock.
The price-to-sales ratio (P/S) of IGC Pharma is currently 17.29. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the IGC Pharma stock.
The Eulerpool Quality Score for IGC Pharma is 4/10.
The ISIN of IGC Pharma is US45408X3089. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of IGC Pharma is A1T87A. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of IGC Pharma is IGC. The ticker symbol is used to trade IGC Pharma shares on the stock exchange.
IGC Pharma stock
IGC Pharma Peer Group
IGC Pharma Ticker
IGC Pharma FIGI
All fundamentals and in-depth analysis of IGC Pharma
Our stock analysis for IGC Pharma stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of IGC Pharma. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.